Trial Profile
Postmarketing Cardiovascular Ischemia and Torsades de Pointes Monitoring for Pazopanib Using Observational Databases
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Sep 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Bevacizumab; Sorafenib; Sunitinib
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 26 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Feb 2013 Planned number of patients (1) as reported by ClinicalTrials.gov.
- 21 Feb 2013 Planned End Date changed from 1 Dec 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.